Navigation Links
FRC Action and Pro-Life Coalition Urge the FDA to Reject New Abortion-Causing Drug
Date:7/28/2010

WASHINGTON, July 28 /PRNewswire-USNewswire/ -- Today FRC Action joined 19 pro-life groups in a letter sent to Food and Drug Administration (FDA) Commissioner Margaret Hamburg requesting that Ella, a drug under consideration for FDA approval that can cause abortions but is misleadingly labeled as an "emergency contraceptive," not be approved.

Tom McClusky, FRC Action's Senior Vice President, made the following comments:

"The Obama Administration has repeatedly promised a commitment to science and transparency, but approval of Ella as an 'emergency contraceptive' would deny women the right to informed consent on something as important as a baby's life and their health. Ella can cause an abortion after implantation, just like RU-486.

"Additionally, given the recently enacted Obama health care plan, approval of this drug could open yet another backdoor to taxpayer funding of abortions," McClusky concluded.

Click here to download FRC's new Ella fact sheet, "Myth and Fact: The Truth About Ella and How it Works."

http://www.frc.org/get.cfm?i=IF10G01

Click here to download a copy of the group letter to FDA Commissioner Margaret Hamburg.

http://www.frc.org/ella-group-letter


'/>"/>
SOURCE Family Research Council Action
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
3. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
4. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
5. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
6. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
7. Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action
8. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
9. ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI
10. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
11. Genmab A/S - Company Announcement: Novel Insights into HuMax-EGFr Mechanisms of Action Published in PNAS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... , Feb. 17, 2017   ... to protecting the rights of victims injured by ... prompted regulators to call for better reporting. Congress ... Safety concerns involving power morcellators and ... (FDA) to investigate how hospitals report injuries and ...
(Date:2/17/2017)... According to a new market research report ... Application (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End User (Healthcare ... the market is expected to reach USD 330.6 Million by 2021 ... from 2016 to 2021. Continue Reading ... ...
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and Rest ... through 2022. Also, a six-year historic analysis is provided for these markets. ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... ... sustainable systems change designed to further positively impact the health and wellness of ... has long considered it our duty to seriously consider releasing our assets beyond ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. ... distinguish between corrective action (CA) and preventive action (PA)? , The methods share ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
(Date:2/16/2017)... AL (PRWEB) , ... February 17, 2017 , ... ... protection assistance and financial planning services to families and entrepreneurs in the Birmingham ... a local adoptive mother who needs assistance with her medically challenged son, Anius. ...
Breaking Medicine News(10 mins):